CONCLUSIONS: These findings confirm that abnormalities of the N1 and P2 components are robust biomarkers of altered sensory processing in FXS and suggest that these alterations may present a dose-response relation to clinical impairments in FXS.
CONCLUSIONS: These findings confirm that abnormalities of the N1 and P2 components are robust biomarkers of altered sensory processing in FXS and suggest that these alterations may present a dose-response relation to clinical impairments in FXS.